Listed

Sanofi: Form 20-F for the period ended Dec 31, 2022

Filed with the SEC on Feb 24, 2023 and accepted by EDGAR at Feb 24, 2023, 10:25 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2022-01-01 to 2022-12-31EUR 13.70bnifrs-full:CostOfSales
Gross profit12 months2022-01-01 to 2022-12-31EUR 31.69bnifrs-full:GrossProfit
Operating income12 months2022-01-01 to 2022-12-31EUR 10.66bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2022-01-01 to 2022-12-31EUR 2.01bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2022-01-01 to 2022-12-31EUR 8.37bnifrs-full:ProfitLossAttributableToOwnersOfParent
Operating cash flow12 months2022-01-01 to 2022-12-31EUR 10.53bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2022-12-31EUR 12.74bnifrs-full:CashAndCashEquivalents
Total assetsAt period end2022-12-31EUR 126.72bnifrs-full:Assets
Shareholders' equityAt period end2022-12-31EUR 74.78bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2022-12-311,260,835,732 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001121404-23-000008. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.